Literature DB >> 6544815

Portrayal of pheochromocytoma and normal human adrenal medulla by m-[123I]iodobenzylguanidine: concise communication.

M D Lynn, B Shapiro, J C Sisson, D P Swanson, T J Mangner, D M Wieland, L J Meyers, J V Glowniak, W H Beierwaltes.   

Abstract

The radiopharmaceutical m-[131I]iodobenzylguanidine (I-131 MIBG), which is readily taken up by adrenergic vesicles, produces scintigraphic images of pheochromocytomas in man but rarely visualizes normal adrenal glands. Iodine-123 has many potential advantages over I-131 as a radiolabel for MIBG, including shorter half-life, freedom from beta emissions, and increased gamma-camera efficiency. In this study, diagnostic doses of MIBG labeled with I-131 and I-123, with nearly equivalent radiation dosimetry, were compared as imaging agents in eight patients with known or suspected pheochromocytoma. Images of superior quality were obtained with I-123 MIBG, and lesions not visualized using I-131 MIBG were portrayed. In addition, the normal adrenal medullae were visualized on the I-123 MIBG scintigrams in six out of eight patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6544815

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

1.  131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Francesco Giammarile; Cumali Aktolun; Richard P Baum; Angelika Bischof Delaloye; Lorenzo Maffioli; Roy Moncayo; Luc Mortelmans; Giovanna Pepe; Sven N Reske; Maria R Castellani; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12       Impact factor: 9.236

2.  The role of I-131-MIBG in the diagnosis and therapy of carcinoids.

Authors:  C A Hoefnagel; F C den Hartog Jager; B G Taal; N G Abeling; E E Engelsman
Journal:  Eur J Nucl Med       Date:  1987

Review 3.  Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry.

Authors:  A R Wafelman; C A Hoefnagel; R A Maes; J H Beijnen
Journal:  Eur J Nucl Med       Date:  1994-06

Review 4.  Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer.

Authors:  Ioannis Ilias; Chaitanya Divgi; Karel Pacak
Journal:  Semin Nucl Med       Date:  2011-09       Impact factor: 4.446

Review 5.  Magnetic resonance imaging or metaiodobenzylguanidine scintigraphy for the demonstration of paragangliomas? Correlations and disparities.

Authors:  A P van Gils; A R van Erkel; T H Falke; E K Pauwels
Journal:  Eur J Nucl Med       Date:  1994-03

6.  Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial.

Authors:  Gregory A Wiseman; Karel Pacak; Mary S O'Dorisio; Donald R Neumann; Alan D Waxman; David A Mankoff; Sherif I Heiba; Aldo N Serafini; Sabah S Tumeh; Natalie Khutoryansky; Arnold F Jacobson
Journal:  J Nucl Med       Date:  2009-08-18       Impact factor: 10.057

7.  Utility of thallium-201 and iodine-123 metaiodobenzylguanidine in the scintigraphic detection of neuroendocrine neoplasia.

Authors:  F Montravers; G Coutris; L Sarda; B Mensch; J N Talbot
Journal:  Eur J Nucl Med       Date:  1993-11

Review 8.  New imaging approaches to phaeochromocytomas and paragangliomas.

Authors:  Bas Havekes; Kathryn King; Edwin W Lai; Johannes A Romijn; Eleonora P M Corssmit; Karel Pacak
Journal:  Clin Endocrinol (Oxf)       Date:  2009-06-08       Impact factor: 3.478

9.  Age-related decrease in cardiopulmonary adrenergic neuronal function in children as assessed by I-123 metaiodobenzylguanidine imaging.

Authors:  Wengen Chen; Elias H Botvinick; Abass Alavi; Yifan Zhang; Steven Yang; Rodolfo Perini; Hongming Zhuang
Journal:  J Nucl Cardiol       Date:  2008 Jan-Feb       Impact factor: 5.952

10.  Nuclear medicine imaging in the evaluation of endocrine hypertension.

Authors:  Punit Sharma; Rakesh Kumar
Journal:  Indian J Endocrinol Metab       Date:  2012-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.